Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Readies Bardoxolone For Phase III Looking At Kidney Function Outcomes

This article was originally published in The Pink Sheet Daily

Executive Summary

Further Phase II data show biomarker evidence, and Reata will now look to a 1,600-patient Phase III trial to prove the drug can lead to improved kidney function.
Advertisement

Related Content

Abbott Adds To Renal Pipeline In Deal With Action Pharma
With Generous Partner Abbott Back For More, Reata Aims High Again
Reata Hopes To Beat Competition To Market With Abbott Deals
Abbott Pays $400 Million Upfront For Reata’s Preclinical AIM Programs
Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug

Topics

Advertisement
UsernamePublicRestriction

Register

PS072422

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel